It is imperative that participants fully meet all eligibility criteria. 6.3 Lifestyle Restrictions There are no lifestyle restrictions applicable for this study given that the participants will receive the study investigational products (IPs) intravenously. 6.4 Screen Failures Screen failures are defined as participants who consent to participate in the clinical study but are not subsequently randomized/entered in the study/included in the analysis population. A minimal set of screen failure information is required to ensure transparent reporting of screen failure Revised Protocol No.: 04 Date: 31-May-2019 80 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS participants, to meet the Consolidated Standards of Re porting Trials (CONSORT) publishing requirements (see Appendix 8 ), and to respond to queries from regulatory authorities. Minimal information includes date of c onsent, demography, screen failure details, eligibility criteria, and any SAEs. 6.4.1 Retesting During Screening This study permits the re-enrollment of a participant who has discontinued the study as a pretreatment failure (ie, participant has not been randomized/has not been treated). If re-enrolled, the participant must be re-consented. Retesting of laboratory parameters and/or other assessments within any single screening period will be permitted (in addition to any parameters that require a confirmatory value). The most current result prior to randomization is the value by which study inclusion will be assessed because it represents the participant’s most current, clinical state. Laboratory parameters and/or assessments that are included in Table 2-1 may be repeated in an effort to find all possible well- qualified participants. Consu ltation with the BMS Medical Monitor/Study Dir ector (or designee) may be needed to identify whether repeat testing of any particular parameter is clinically relevant.7T R E A T M E N T Study treatment is defined as any investigati onal treatment(s) or marketed product(s) intended to be administered to a study participant acc ording to the study randomization or tr eatment allo cation. Study treatment includes IPs/investigational medicinal products (IMPs) and non-IPs/IMPs and can consist of the following: •BMS-986226 •Nivolumab •Ipilimumab •Tetanus Vaccine An IP, also known as IMP in some regions, is defined as a pharmaceut ical form of an active substance or placebo being tested or used as a reference in a clinical study, including products already with a marketing authorization but used or assembled (formulated or packaged) differently from the authorized form, used for an unauthorized ind ication, or when used to gain further information about the authorized form. Other medications used as support or escape medication for preventative, dia gnostic, or therapeutic reasons, as components of the standard of care for a given dia gnosis, may be considered as non-IPs. Revised Protocol No.: 04 Date: 31-May-2019 81 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 7-1: Study Treatments for CA021002 Product Description / Dosage FormPotency IP/NonIMP Blinded or Open LabelPackaging / AppearanceStorage Conditions (per Label) BMS-986226-01 Solution for Injection10 mg/mL IP Open Vial 2 to 8 °C, Protect from light NivolumabSolution for Injection10 mg/mL IP Open Vial 2 to 8 °C, Protect from light and freezing IpilimumabSolution for Injection 5 mg/mL IP Open Vial 2 to 8 °C, Protect from light and freezing Tetanus vaccinePer locala IP Open Various packaging configurationRefer to the label on container and/or pharmacy manual Abbreviations: IP = investigational product a Tetanus vaccine (Tdap preferred, Td or equivalent after discussion with the Medical Monitor/Study Director or designee) will be obtain ed as local commercial product in countries if allowed by local regu lations or through investigating sites standard prescribing procedures . 7.1 Treatments Administered The selection and timing of dose for each participant are presented in Table 7.1-1. Table 7.1-1: Selection and Timing of Dose per Part Study Treatment Dose Level Frequency of AdministrationRoute of AdministrationInfusion time (Minute) Preliminary Safety Cohorts and Part A BMS-9862262, 8, 25, 80, 200, 400, 800 mg Q4W IV30 Part B1 Nivolumab 480 mgQ4W IV30 BMS-9862263 Doses evaluated by BLRM-copula, PK/PDQ12W 30 Part B2 Nivolumab 480 mg Q4W IV 30 BMS-9862263 Doses evaluated by BLRM-copula, PK/PDQ4W IV 30 Part C1 Ipilimumab 3 mg/kgaQ4W IV30 BMS-9862263 Doses evaluated by BLRM-copula, PK/PDQ12W 30 Revised Protocol No.: 04 Date: 31-May-2019 82 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 7.1-1: Selection and Timing of Dose per Part Study Treatment Dose Level Frequency of AdministrationRoute of AdministrationInfusion time (Minute) Part C2 Ipilimumab 3 mg/kgaQ4W IV30 BMS-9862263 Doses evaluated by BLRM-copula, PK/PDQ4W 30 Part D Nivolumab 480 mg Q4W IV30 BMS-986226 PK/PD from Part B TBD 30 Part E Ipilimumab 3 mg/kgaQ4W IV 30 BMS-986226 PK/PD from Part C TBD IV 30 aWeight collected at baseline/screening should be used to calculate ipilimumab dose unless weight has changes more than +/- 10% from baseline on C1D1 Note: In Parts B, C, D, and E a 30-minute infusion of either nivolumab or ipilimumab will be followed by a 30-minute observation period, followed by a 30-minute infusion of BM S-986226. In all parts, participants will be observed for at least 60 minutes following the completion of BMS-986226 infusion due to the potential risk of, and to monitor for, infusion reactions.